Stockscreener 앱 받기
0.8446
5.18%
-0.0461
시간 외 거래:
.87
0.0254
+3.01%
Werewolf Therapeutics Inc 주식(HOWL)의 최신 뉴스
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline - Yahoo Finance
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Friday - Defense World
Werewolf Therapeutics stock maintains $4 target, Market Outperform By Investing.com - Investing.com India
Werewolf Therapeutics stock maintains $4 target, Market Outperform - Investing.com
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewswire
Cancer Drug Developer Werewolf Therapeutics Strengthens Leadership Team Amid Promising Clinical Results - Stock Titan
Werewolf Therapeutics names Steven Bloom as CBO - The Pharma Letter
Werewolf Therapeutics stock hits 52-week low at $0.85 - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $0.85 By Investing.com - Investing.com South Africa
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Werewolf Therapeutics Reveals Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Bank of New York Mellon Corp Grows Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics stock hits 52-week low at $1.02 By Investing.com - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $1.02 - Investing.com India
Werewolf Therapeutics Reports 2024 Financial Results and Progress - TipRanks
HC Wainwright Issues Pessimistic Outlook for HOWL Earnings - Defense World
Wedbush Research Analysts Cut Earnings Estimates for HOWL - Defense World
HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Wedbush Reaffirms Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China - TipRanks
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Inc. (HOWL) reports earnings - Quartz
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c) - TipRanks
Werewolf Therapeutics, Inc. SEC 10-K Report - TradingView
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bakersfield.com
HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference - GlobeNewswire
What Will Werewolf Therapeutics Reveal at the Leerink Biopharma Conference Next Month? - StockTitan
Werewolf Therapeutics, Inc. Announces Board Changes and Committee Appointment - Marketscreener.com
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock hits 52-week low at $1.25 - Investing.com
Werewolf Therapeutics Announces Board Resignation and New Appointment - Defense World
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - GlobeNewswire
Werewolf Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Werewolf Therapeutics appoints new board member - Investing.com India
Can This Oncology Pioneer Transform Werewolf's Cancer-Fighting Platform? - StockTitan
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
0.19%
자본화:
|
볼륨(24시간):